Home>>Signaling Pathways>> Others>>Ethyl docosa-4,7,10,13,16,19-hexaenoate

Ethyl docosa-4,7,10,13,16,19-hexaenoate

Catalog No.GC33796

Ethyl cis-4,7,10,13,16,19-Docosahexaenoate, the ethyl ester of Docosahexaenoate (DHA), is enriched in the ethyl ester fraction by the selective alcoholysis of fatty acid ethyl esters originating from tuna oil with lauryl alcohol.

Products are for research use only. Not for human use. We do not sell to patients.

Ethyl docosa-4,7,10,13,16,19-hexaenoate Chemical Structure

Cas No.: 84494-72-4

Size Price Stock Qty
10mM (in 1mL DMSO)
$99.00
In stock
50mg
$91.00
In stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Customer Reviews

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Ethyl cis-4,7,10,13,16,19-Docosahexaenoate, the ethyl ester of Docosahexaenoate (DHA), is enriched in the ethyl ester fraction by the selective alcoholysis of fatty acid ethyl esters originating from tuna oil with lauryl alcohol.

Ethyl cis-4,7,10,13,16,19-Docosahexaenoate (Ethyl docosahexaenoate; E-DHA) is efficiently enriched by the selective alcoholysis of ethyl esters originating from tuna oil with lauryl alcohol using immobilized lipase[1].

[1]. Yuji Shimada, et al. Purification of ethyl docosahexaenoate by selective alcoholysis of fatty acid ethyl esters with immobilized Rhizomucor miehei lipase. J Am Oil Chem Soc. 1998 Nov, 75(11): 1565-1571.

Reviews

Review for Ethyl docosa-4,7,10,13,16,19-hexaenoate

Average Rating: 5 ★★★★★ (Based on Reviews and 28 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Ethyl docosa-4,7,10,13,16,19-hexaenoate

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.